

10th February 2012

ASX ANNOUNCEMENT

ASX INTERIM GUIDANCE

Analytica Limited (*the Company*) advises that it anticipates a loss for the half year ended 31st December 2011 of approximately \$1.5 Million (480k H1 2010). The result, compared to H1 2010 is attributed to increased expenditure on Research and Development, rights issue costs, write off of intellectual property together with reduction of fair value of CBio shares.

Further details will be provided when the Company's half year results are finalised.

For, and on behalf of the board,

Dr M. Monsour

Chairman.

Analytica Limited (ASX:ALT) is an Australian company dedicated to the design, development and supply of Class I and IIa medical devices. Analytica's focus is on the product development and commercialisation of a range of medical devices and pharmaceutical implants.

